165 related articles for article (PubMed ID: 37645217)
1. Identifying structural and dynamic changes during the Biliverdin Reductase B catalytic cycle.
Lee E; McLeod MJ; Redzic JS; Marcolin B; Thorne RE; Agarwal P; Eisenmesser EZ
Front Mol Biosci; 2023; 10():1244587. PubMed ID: 37645217
[TBL] [Abstract][Full Text] [Related]
2. Biliverdin Reductase B Dynamics Are Coupled to Coenzyme Binding.
Paukovich N; Xue M; Elder JR; Redzic JS; Blue A; Pike H; Miller BG; Pitts TM; Pollock DD; Hansen K; D'Alessandro A; Eisenmesser EZ
J Mol Biol; 2018 Sep; 430(18 Pt B):3234-3250. PubMed ID: 29932944
[TBL] [Abstract][Full Text] [Related]
3. Modulating Enzyme Function
Redzic JS; Duff MR; Blue A; Pitts TM; Agarwal P; Eisenmesser EZ
Front Mol Biosci; 2021; 8():691208. PubMed ID: 34095235
[TBL] [Abstract][Full Text] [Related]
4. Structure, dynamics and function of the evolutionarily changing biliverdin reductase B family.
Duff MR; Redzic JS; Ryan LP; Paukovich N; Zhao R; Nix JC; Pitts TM; Agarwal P; Eisenmesser EZ
J Biochem; 2020 Aug; 168(2):191-202. PubMed ID: 32246827
[TBL] [Abstract][Full Text] [Related]
5. Enzymatic Activity and Thermodynamic Stability of Biliverdin IXβ Reductase Are Maintained by an Active Site Serine.
Chu WT; Nesbitt NM; Gnatenko DV; Li Z; Zhang B; Seeliger MA; Browne S; Mantle TJ; Bahou WF; Wang J
Chemistry; 2017 Feb; 23(8):1891-1900. PubMed ID: 27897348
[TBL] [Abstract][Full Text] [Related]
6.
Nesbitt NM; Zheng X; Li Z; Manso JA; Yen WY; Malone LE; Ripoll-Rozada J; Pereira PJB; Mantle TJ; Wang J; Bahou WF
J Biol Chem; 2018 Apr; 293(15):5431-5446. PubMed ID: 29487133
[TBL] [Abstract][Full Text] [Related]
7. Biliverdin reductase B impairs cholangiocarcinoma cell motility by inhibiting the Notch/Snail signaling pathway.
Gao Z; Ni X; Zheng B; Sun W; Wan W; Liu H; Ni X; Suo T; Li N; Liu H; Shen S
J Cancer; 2022; 13(7):2159-2170. PubMed ID: 35517415
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Functions of Biliverdin IXβ Reductase in Redox-Regulated Hematopoietic Cell Fate.
Bahou WF; Marchenko N; Nesbitt NM
Antioxidants (Basel); 2023 May; 12(5):. PubMed ID: 37237924
[TBL] [Abstract][Full Text] [Related]
9. Characterization of enzyme motions by solution NMR relaxation dispersion.
Loria JP; Berlow RB; Watt ED
Acc Chem Res; 2008 Feb; 41(2):214-21. PubMed ID: 18281945
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of biliverdins IXβ/δ generated by a selective heme oxygenase.
Zhang B; Nesbitt NM; Pereira PJB; Bahou WF
Biochem J; 2020 Feb; 477(3):601-614. PubMed ID: 31913441
[TBL] [Abstract][Full Text] [Related]
11. Structural and dynamic insights into substrate binding and catalysis of human lipocalin prostaglandin D synthase.
Lim SM; Chen D; Teo H; Roos A; Jansson AE; Nyman T; Trésaugues L; Pervushin K; Nordlund P
J Lipid Res; 2013 Jun; 54(6):1630-1643. PubMed ID: 23526831
[TBL] [Abstract][Full Text] [Related]
12. Heme degradation enzyme biliverdin IXβ reductase is required for stem cell glutamine metabolism.
Li Z; Nesbitt NM; Malone LE; Gnatenko DV; Wu S; Wang D; Zhu W; Girnun GD; Bahou WF
Biochem J; 2018 Mar; 475(6):1211-1223. PubMed ID: 29500232
[TBL] [Abstract][Full Text] [Related]
13. Detection of organometallic and radical intermediates in the catalytic mechanism of methyl-coenzyme M reductase using the natural substrate methyl-coenzyme M and a coenzyme B substrate analogue.
Dey M; Li X; Kunz RC; Ragsdale SW
Biochemistry; 2010 Dec; 49(51):10902-11. PubMed ID: 21090696
[TBL] [Abstract][Full Text] [Related]
14. Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
Kim M; Ha JH; Choi J; Kim BR; Gapsys V; Lee KO; Jee JG; Chakrabarti KS; de Groot BL; Griesinger C; Ryu KS; Lee D
J Med Chem; 2022 Feb; 65(3):2548-2557. PubMed ID: 34957824
[TBL] [Abstract][Full Text] [Related]
15. Biliverdin Reductase B Is a Plasma Biomarker for Intraplaque Hemorrhage and a Predictor of Ischemic Stroke in Patients with Symptomatic Carotid Atherosclerosis.
Chemaly M; Marlevi D; Iglesias MJ; Lengquist M; Kronqvist M; Bos D; van Dam-Nolen DHK; van der Kolk A; Hendrikse J; Kassem M; Matic L; Odeberg J; de Vries MR; Kooi ME; Hedin U
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371462
[TBL] [Abstract][Full Text] [Related]
16. Divergent erythroid megakaryocyte fates in Blvrb-deficient mice establish non-overlapping cytoprotective functions during stress hematopoiesis.
Nesbitt NM; Malone LE; Liu Z; Jares A; Gnatenko DV; Ma Y; Zhu W; Bahou WF
Free Radic Biol Med; 2021 Feb; 164():164-174. PubMed ID: 33359909
[TBL] [Abstract][Full Text] [Related]
17. Enzyme dynamics from NMR spectroscopy.
Palmer AG
Acc Chem Res; 2015 Feb; 48(2):457-65. PubMed ID: 25574774
[TBL] [Abstract][Full Text] [Related]
18. Structural assembly of the active site in an aldo-keto reductase by NADPH cofactor.
Sanli G; Blaber M
J Mol Biol; 2001 Jun; 309(5):1209-18. PubMed ID: 11399090
[TBL] [Abstract][Full Text] [Related]
19. On the mechanism of biological methane formation: structural evidence for conformational changes in methyl-coenzyme M reductase upon substrate binding.
Grabarse W; Mahlert F; Duin EC; Goubeaud M; Shima S; Thauer RK; Lamzin V; Ermler U
J Mol Biol; 2001 May; 309(1):315-30. PubMed ID: 11491299
[TBL] [Abstract][Full Text] [Related]
20. Conformational changes in the active site loops of dihydrofolate reductase during the catalytic cycle.
Venkitakrishnan RP; Zaborowski E; McElheny D; Benkovic SJ; Dyson HJ; Wright PE
Biochemistry; 2004 Dec; 43(51):16046-55. PubMed ID: 15609999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
